Global Investor Forum Contact

Peter de Keizer

Group Leader “Senescence in Cancer and Aging”, UMC Utrecht

Session

14:15 - 15:25 hours
From research to innovation

Peter de Keizer received his PhD from Utrecht University Medical Center in 2009 for his work on FOXO transcription factors in tumor suppression. He received his postdoctoral training at the Buck Institute for Research on Aging in Novato, CA, USA on the molecular hallmarks of cellular senescence for which in 2010, he was elected as a fellow of the Dutch Cancer Society (KWF). In 2012 he joined the Erasmus University Medical Center in Rotterdam where in 2014 he was awarded the prestigious “Talent Extraordinary Award” and is currently a group leader in “Senescence in Cancer in Aging”

His research focusses on targeting the deleterious role of senescent cells. Senescence has been causally linked to age-related diseases, including cancer progression and therapy resistance. He designed a cell penetrating peptide, called FOXO4-DRI or Proxofim, which selectively eliminates senescent cells and thereby can counter signs of chemotoxicity and aging in mice. This work was published in Cell in March 2017 and received numerous exposure worldwide, including coverage in TV shows and radio programs. His current focus lies on further optimizing this peptide and assessing the potential benefit such compounds may have on late stage cancer and specific age-related diseases. His aim is to take an active stance in promoting clinical translation when the results prove to be fruitful.

Abstract

Targeting Senescence Against aging and Cancer
Senescent cells are a cause for certain aspects of aging and can confer resistance of cancer cells to therapy. As we showed recently (Baar et al, 2017, Cell), FOXO4 is a pivot in the maintenance of senescent cells viability and targeting the FOXO4-p53 pathway with specific peptides can result in health benefits in aging mice. Our goal is to improve these compounds to eventually be ready for human translation, specifically against lethal types of cancer.

Kees Been
Lysosomal Therapeutics Inc.

Erik van de Berg
AM-Pharma

René Bernards
Qameleon Therapeutics & NKI

Annelien Bredenoord
UMC Utrecht

Carine van den Brink
AXON Lawyers

Danielle Curfs
Chemelot InSciTe
Jenny Dankelman
TU Delft
Diederik Dippel
Erasmus MC

Cornelia van Duijn
Erasmus MC

Lude Franke
UMCG
Thibault Helleputte
DNAlytics
Mark van Houdenhoven
St. Maartenskliniek
Henk Joos
Flanders Bio
Peter de Keizer
UMC Utrecht
Tim Knotnerus
AM-Pharma, PRIMER Professionals
Angus Livingstone
Oncode Institute
Travis McCready
Massachusetts Life Sciences Center

Mirjam Mol
Pivot Park

Barend Mons
DTL & LUMC
Timothy Noël
Eindhoven University of Technology
Jacquelien Noordhoek
Dutch CF Foundation
Violet Petit-Steeghs
Athena Institute
Thomas Plochg
NPHF

Gerard van Oortmerssen
Patientenplatform Sancomen

Anne Portwich
LSP
Elisabeth van Rossum
Erasmus MC
André van de Sande
Xendo
Marlies Schijven
AMC
Hans Schikan
Topsector LSH
Hanneke Schuitemaker
Janssen Vaccines
Frits Schut
V.O. Patents & Trademarks
Marieke Schuurmans
UMC Utrecht
Jacob Seidell
VU
Agaath Sluijter
Medical Delta
Thijs Spigt
Erasmus MC
Marianne van der Steen
Maastricht University
Maarten Steinbuch
Eindhoven University of Technology
Onno van de Stolpe
Galapagos
Werner Verbiest
Janssen Diagnostics
Martine de Vries
LUMC

Edward van Wezel
BioGeneration Ventures

Jan van de Winkel
Genmab

Loek Winter
DC Klinieken

Hanneke Heeres
Health~Holland
Caroline Duterloo
Medical Delta
Paul Korte
Janssen
Aart Jan van der Lelij
Erasmus MC
Werner Brouwer
Erasmus University
Arnout van Diermen
Novo Nordisk

Ton van der Steen
Erasmus MC & Medical Delta

Sven de Langen
Gemeente Rotterdam
Sponsors & Partners 2018
Main partner
Host sponsor
Host sponsor
Host sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Gold sponsor
Silver sponsor
Award sponsor
Award sponsor
© 2018 Innovation for Health